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Scientific researchers in biomedicine, pharmaceutical science and toxicology often face situations in 
which binary logistic regression model fits are used to compare two drugs or substances, often by means 
of comparisons of median doses or concentrations (EC50 or LD50).  Applications are given in works 
spanning early bioassay findings of Finney (1971,1978) to more recent results in Rich (2013) and Gupta 
and Vale (2017).  Furthermore, Wheeler et al. (2006) underscores the caution that instead of examining 
for overlap in separate EC50 confidence intervals, testing is best based on estimation and confidence 
intervals associated with the relative potency parameter.  Notably, before fitting such curves and testing 
for differing potencies, an important requirement is that these dose response curves be parallel.  As 
such, various works have introduced meaningful means to assess parallelism in logistic regression 
settings, including Gottschalk and Dunn (2005), Jonkman and Sidak (2009), Novick et al. (2012), Yang and 
Zhang (2012), Yang et al. (2012), Fleetwood et al. (2015) and Sidak and Jonkman (2016). 
 
So as to efficiently test for common slopes of drug curves, our focus here is on developing robust, 
efficient and practical design strategies in the assessment of dose response curve parallelism. 
Overviews of optimal design theory and applications are given in O’Brien and Funk (2003) and Atkinson 
et al. (2007).  Additionally, classical experimental design strategies for binary logistic regression models 
are given in Abdelbasit and Plackett (1983), Minkin (1987) and Kalish (1990), and model-robust design 
approaches are given and explored in Atkinson (1972), O’Brien (2005), O’Brien (2016), O’Brien (2018), 
O’Brien and Rawlings (1996), O’Brien and Lim (2018), O’Brien et al. (2009) and O’Brien et al. (2010).   
 
2. Assessing Parallelism in Dose Response 
 
In situations where the outcome variable is a percentage derived from binary outcomes – such as 
percentage mortality in a microbiology or toxicology experiment – the two-parameter (binomial, logit-
link) logistic model is often used to model the dose-response data.  This generalized nonlinear model is 
written 
 
    (
 
   
)           (1) 
 
Here,   is the probability of outcome (e.g., mortality),   is the slope,   is the concentration or dose of 
the drug or compound, and   is the EC50/LD50 parameter so that     coincides with   
 
 
 (or 50% 
chance of death).  Equivalent to (1) is the expression   
       
         
.  This model can be extended to 
simultaneously model two curves (such as corresponding to two viruses or drugs, labelled “A” and “B”), 
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 (2) 
 
In (2),   is the slope of the drug A curve,       is the slope of the drug B curve, and the respective 
EC50’s are    and    for drugs A and B. Our goal in fitting this model is to fit the respective curves with 
particular focus on the difference-of-slopes parameter  .  Both curves can be written in a single model 
as   
  
    
 with   here given in (2).  It is important to point out that both curves are fit – and indeed 
designed – simultaneously since they share the joint parameter  . These curves are plotted in Figure 1 – 





Figure 1.  Plot of parallel (   ) binary logistic curves with vertical axis corresponding to probability of 
outcome or mortality, slope        and EC50’s         (left curve) and         (right curve); 
here, relative potency is then estimated to be               .  Solid squares indicate EC50’s as points 
where the respective curves cross cut-line,      . 
 
 




Approximate designs, denoted  , are written 
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} (3) 
 
The   are non-negative design weights which sum to one, and the    are design points (i.e., 
concentrations) that belong to the design space and are not necessarily distinct.  Further, the   model 
parameters are stacked into the p-vector               .  In the constant-variance Normal/Gaussian 




with                  ,the     (Fisher) information matrix is written 
 
             (4) 
 
Atkinson et al (2007) demonstrates that for binomial logistic models in general, the information matrix 
for the relative-potency logistic model considered here has the same form as in (4) with a modification 
of the weight matrix .  Specifically,  in this case is a diagonal matrix with     diagonal element 
          , where    is the success probability.  In regression settings, since the (asymptotic) variance 
of the maximum-likelihood estimator  ̂    is proportional to 
       , designs are often chosen to 
minimize some (convex) function of        .  For example, designs which minimize the determinant 
of    – and equivalently which maximize the determinant of  – are called D-optimal. 
 
Since our focus is on the difference-of-slopes parameter ( ) more so than the other parameters, we 




      
      
] (5) 
 
Each sub-matrix    is of dimension       for        , and        .  The parameter vector is 
also partitioned,   (
  
  
) with    (the so-called nuisance parameters) of dimension      and    (the 
parameter of interest) of dimension     .  In the current situation,   
            so      and 
     so     .  As outlined in Atkinson et al. (2007),  (  ) subset designs maximize 
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     |  
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 (6) 
 
Because of problems associated with subset designs, some authors suggest combining the subset and 
full parameter criteria so that for a given   [
  
 
  ], designs be chosen to maximize the compound 
objective function (see O’Brien (2005) and Atkinson et al. (2007)), 
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A generalized inverse is used in (7) when    is not invertible.  This objective function ranges from the 
D-optimal criterion for   
  
 
 to the subset design criterion (for  ) in (6) for    .  For a given choice 
of   [
  
 
  ], we call designs that maximize (7)  -optimal designs. 
 
Extending the results given in O’Brien (2016), our results here for the two-logistic situation in (2) and 
Figure 1 validate that the optimal values of      for  -optimal designs satisfy the expression, 
 
                       (8) 
 
In (8),   
            
              
.  The  -values which solve this expression are observed to be reciprocals, and 
this has been demonstrated to be the case in other situations when working with logistic regression (see 
O’Brien (2016), O’Brien and Lim (2018), and O’Brien et al. (2009)).  As in these other situations, Equation 
(8) has exactly two roots for   [
  
 
  ].  For example, for   
  
 
      (i.e., the D-optimality 
criterion),     and solution of (8) gives           (and    
  
    
       ) and           (and 
         ).  As   approaches unity (i.e., the  ( ) subset design), we obtain   
 
 
,           (and 
         ) and            (and          ).  Since the   values here are reciprocals, the 
corresponding values of   necessarily sum to one. 
 
Figure 2 shows the D-optimal design points along with the corresponding cut-lines at           and 
         .  The values of the design support points are obtained using the relations      
 
 
         for drug A (left curve in Figure 2) and      
 
     
         for drug B (right curve in Figure 2).  
Thus, for the specific parameter values used here, the support points are                  for drug 







Figure 2.  Plot of parallel (   ) binary logistic curves with vertical axis corresponding to probability of 
outcome/mortality, slope        and EC50’s         (left curve) and         (right curve), along 
with respective D-optimal design points (circles on respective curves).  Cut-lines at           and 




A measure of the distance between an arbitrary design   and a D-optimal design   
  is the D-efficiency 
(    ) given by the expression (
|    |
| (  
 )|
)
   
 (see O’Brien and Funk (2003) and Atkinson et al. (2007)).  A 
similar D-efficiency expression (     ) can be given for subset efficiency in (6) but using |    
      
     | in place of | | in both numerator and denominator and raised to the power (    ) 
instead of (   ).  For the current situation, full and subset efficiencies of the D-optimal and the  ( ) 
subset design are given in Table 1.  Note that as one shifts from the D-optimal to the  ( ) subset design 
(i.e., as   increases from      to    ), the design support points spread out away from the EC50s since 
the proportion cut lines (see Figure 2) drop from          to          and increase from 
         to         .  Also, as we shift from the D-optimal to the subset design, as expected we 
note the decrease in the variance term (diagonal term in   ) associated with   of over     (from 
       to       ) but also the approximately 90% increase in the variance terms associated with the   
(EC50) terms (from       to      ).  Finally, in noting the efficiency values of these two designs, one 






Table 1. - and  ( )-optimal designs in the parallel logistic setting: design support points and corresponding 
proportions, associated variance estimates for parameter values, and  - and subset-efficiencies. 
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Translating efficiencies into sample size requirements, note that an efficiency of      of a given design 
relative to an optimal design translates to            .  So, a sample size     higher for the less-
efficient design is needed (compared with the optimal design) to yield equivalent information. 
 
The above advantages in terms of efficiency notwithstanding, optimal designs are often only used as a 
starting point since they often have shortcomings.  In most practical situations, optimal designs for  -
parameter model functions comprise only   support points; this is observed here since the D-optimal 
designs for the two-parameter logistic curves graphed in Figure 2 have only two support points for each 
curve/drug.  As such, these designs provide little or no ability to test for lack of fit of the assumed model.  
As a result, researchers often desire near-optimal, so-called “robust”, designs which have extra support 
points that can then be used to test for model adequacy.  Another important disadvantage of the 
optimal designs plotted in Figure 2 is that practitioners typically wish to use the same concentration 
values for both drugs.  In the next section, we introduce and explore very useful strategies to obtain 
near-optimal, robust designs which address these shortcomings. 
 
 
4. Robust Design Approaches 
 
In this section, we propose practical experimental design strategies addressing the lack-of-fit and same-
concentration considerations raised in the previous section.  The requirement that the same 
concentrations be used for both dose-response curves leads us to consider finding the corresponding 
same-concentration-restricted - and  ( )-optimal designs, and this is done in the following section.  
In the subsequent sections, we introduce and examine so-called reflection designs based upon the 
original optimal designs, as well as geometric and uniform designs. 
 
 
4.1. Same-Concentration Designs 
 
In the current illustration – as well as in other situations with the two-drug logistic model in (2) – the 
same-concentration-restricted -optimal design comprises two support points (for both drugs), and this 
is demonstrated in Figure 3 and Table 2.  As demonstrated in Figure 3, the optimal proportions of 
           and            for drug A and            and            for drug B are such 
8 
 
that (1) the lower proportions (    and    ) straddle the cut-line of         from Figure 2 and the 
upper proportions (    and    ) straddle the cut-line of         from Figure 2, and (2) are 




Figure 3. Plot of parallel (   ) binary logistic curves with vertical axis corresponding to probability of 
outcome/mortality, slope        and EC50’s         (left curve) and         (right curve), along 
with same-concentration D-optimal design points (circles on the respective curves).  Cut-lines at 





In examining the first row of Table 3 (i.e. for       , i.e., the -optimal design), note that the same-
concentration D-optimal design yields a D-efficiency (relative to the best design plotted in Figure 2) of 
     ; with a modest      information loss, this design is thus deemed to be highly efficient.  Table 3 
also gives analogous results for the  ( )-optimal (   ) situation, where it is noted that in shifting to 
subset optimality, the design support points and optimal proportions again shift outward away from the 
EC50s.  The subset efficiency of this subset design is      .  Our findings bear out that the patterns and 






Table 2. Same-concentration-restricted - and  ( ) designs in the parallel logistic setting: design support 
points and corresponding proportions, associated variance estimates for parameter values, and - and 
subset-efficiencies. 
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A major disadvantage of the same-concentration restriction is that the resulting near-optimal designs 
are observed to comprise only two support points, and thus provide no ability to check for model 
misspecification.  As such, we now consider the following robust modification of the original 
unrestricted D-optimal design approach illustrated in Figure 2 and Table 1. 
 
 
4.2. Reflection Designs 
 
One means of obtaining robust near-optimal designs (i.e., designs with reasonably high efficiency and 
additional support points) in the two-logistic situation of (2) is to simply use for both drugs each of the 
four distinct concentrations in Figure 2 – that is, the four concentrations where – for at least one of the 
curves –          and         .  We call such designs reflection designs.  For the parameter 
values used here, this situation is illustrated in Figure 4.  The additional reflection   values use 
                
  
    
       
  
    
         and the relations for all such parallel-curve 
(i.e.,    ) reflection design situations are as follows: 
 
    
     
       
       
     
       
       
  
     
            
  
     
      (9) 
 
For the parameter values used here, we obtain                                    






Figure 4.  Plot of parallel (   ) binary logistic curves with vertical axis corresponding to probability of 
outcome/mortality, slope        and EC50’s         (left curve) and         (right curve), cut-
lines at           and            correspond to unrestricted D-optimal design points, and 




For the chosen parameter values, designs, support points, proportion values and summary statistics are 
given in Table 3 for reflection designs for   values in Equation (7) of        (i.e. -optimality), 
       (equal-efficiency), and       (i.e.,  ( )-optimality); note that the equal-efficiency design 
has been chosen so the two efficiency values,     and     , are approximately equal.  It is 
important to note that, with a  -efficiency of      , the -optimal reflection design is observed to be 
highly efficient – i.e., with an efficiency loss of less than   .  This design is also robust in that it provides 
additional support points to test for model lack-of-fit, and it is very practical to use in that scientific 
researchers merely need to sketch the anticipated dose-response curves for the two drugs/substances, 
and obtain design support points resulting from the cut lines at           and           (or 
thereabouts).  The subset efficiency of this design is      ; should a researcher desire higher subset 
efficiency, the value of   could be increased to meet the researcher’s objectives.  For example, the 
equal-efficiency design (      ) results in efficiencies for the full parameter vector and for the   
(difference of slopes) parameter of about    ; in this case, the proportion cut values, at           
and           – or very nearly         and         – are also very practical to implement by 
researchers.  As has been observed above for unconstrained and same-concentration designs, as   
values are increased in (7) to emphasize efficient estimation of the difference-in-slopes parameter ( ), 
the design support points shift out (i.e., away from the EC50’s).  As noted in Table 3, one down-side of 
11 
 
this shift is that the variability associated with these EC50 values increase here by     (from       to 
     ) for        and by     (from       to      ) for      .  We discuss implications of these 




Table 3. Reflection -optimal, equal-efficiencies, and  ( ) designs in the parallel logistic setting with 
parameter values given above: design support points and corresponding proportions, associated variance 
estimates for parameter values, and  - and subset-efficiencies. 
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4.3. Geometric and Uniform Designs 
 
Noting the common-usage of geometric and uniform designs in practical settings, O’Brien (2016) and 
O’Brien et al. (2009) combined the D-optimality criterion with the geometric design structure of the 
form                and the uniform design structure of the form                
  , where  is an adjustment value chosen by the researcher to provide a sufficient number of design 
support points.  We adopt a similar approach here for the two-logistic model and, using the chosen 
parameter values, focus here only on the D-optimality criterion (      ).  (Nonetheless, these results 
generalize to other choices of   as well.)  Results are given in Table 4 for the optimal geometric and 
uniform designs for   ; this choice of  makes these designs comparable with the 4-support-point 




Table 4. Optimal geometric and uniform -optimal designs in the parallel logistic setting with parameter 
values given above: design support points and corresponding proportions, associated variance estimates for 
parameter values, and - and subset-efficiencies. 
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As noted in Table 4, the geometric design yields slightly lower efficiencies compared with the uniform 
design, as well as diverse proportions (i.e., values of  ) and unequal variance terms for the two EC50 
values.  The uniform design, on the other hand, results in a recognizable pattern of proportions (viz, 
                                 ), and somewhat lower variance values.  Both of 
these designs, however, perform slightly worse than the D-optimal (      ) reflection design in the 
previous section in terms of the efficiency measures.  These designs are further examined using 
simulations in the following section. 
 
 
5. Simulation Results 
 
The highlighted designs from the previous sections - and listed below for ease of comparison - were 
each evaluated using simulation methods with        simulations to assess their performance in 




Table 5a. Designs examined in simulations:  each design comprised    observations for both drugs.  Case I 
(small-to-moderate size) with      (i.e.,    observations for both drugs) and Case II (moderate-to-large 
size) with      (i.e.,     observations for both drugs) 
 
Design Description Text Table Replicates Support Points 
1 
Reflection design:        
(Equal Efficiency) 
3 
  observations for each 
drug and each support point 
                 
                
2 
Reflection design:        
(D-optimal) 
3 
  observations for each 
drug and each support point 
        ,         
                
3 
Geometric design:        
(D-optimal) 
4 
  observations for each 
drug and each support point 
                 
                
4 
Uniform design:        
(D-optimal) 
4 
  observations for each 
drug and each support point 
                  
                
5 
Same-concentration design: 
       (D-optimal) 
2 
   observations for each 
drug and each support point 
                 
6 
Same-concentration design: 
      (D-subset) 
2 
   observations for each 
drug and each support point 





As noted in Table 5a, our first simulation, called “Case I: 15/30”, involved the small-to-moderate-sample 
situation of 15 replicates of each of the 4-point designs (designs 1-4) and 30 replicates of each of the 2-
point designs (designs 5 and 6) for each drug – so total sample size of 60.  This process was subsequently 
repeated for the moderate-to-large sample case, called “Case II: 30/60”, which entailed 30 replicates of 
each of the 4-point designs and 60 replicates of each of the 2-point designs for each drug – i.e., total 
sample size of 120.  In each case, independent binary data were generated from the two-logistic 
situation in (2) using parameter values used above, viz,                           .  




Table 5b. Simulations Results for Case I (15/30 study), i.e., with      in Table 5a. 
 
Design Average of  ̂ 
Estimates 
Variance of  ̂ 
Estimates 
Proportion of Simulations  
with | ̂|    
Proportion of Simulations 
with abs-value of |   |    
1  0.0317 2.3625     0.0548 (≈274/5000)     0.0557 (≈278/5000) 
2  0.0058 0.0940 0.0014 (≈7/5000) 0.0014 (≈7/5000) 
3  0.0014 0.0251 0.0002 (≈1/5000) 0.0002 (≈1/5000) 
4 -0.0013 0.0435 0.0012 (≈6/5000) 0.0012 (≈6/5000) 
5 -0.0040 0.2951     0.0510 (≈255/5000)      0.0500 (≈250/5000) 
6  0.0435 0.8514       0.3325 (≈1662/5000)         0.3564 (≈1782/5000) 
 
 
The results in Table 5b confirm – as do additional unreported findings – that as   is chosen other than 
the D-optimal case (      ), estimation of the difference-of-slopes parameter   becomes unstable; 
this is clearly demonstrated by Designs 1 and 6 in Table 5b.  As noted above, in these cases, the design 
support points move away from the EC50 values, and thus estimation of the full parameter vector is also 
unstable; this is demonstrated above in large values of the generalized variance, |   |.  An important 
empirical result observed here is that although our ultimate focus is on assessing the difference-of-
slopes parameter, designs must be chosen to estimate all model parameters in order to be viable.  Also, 
given the weak performance of the same-concentration D-optimal (two-support point) design in Design 
5, this design is also dismissed.  As such, reasonable contenders include only the reflection, geometric 
and uniform D-optimal designs: i.e., Designs 2, 3 and 4.  As samples sizes are doubled for the Case II 
“30/60” (i.e., Table 5c), the situation improves as expected for all designs, but clearly the most viable 




Table 5c. Simulations Results for Case II (30/60 study), i.e., with      in Table 5a. 
 
Design Average of  ̂ 
Estimates 
Variance of  ̂ 
Estimates 
Proportion of Simulations  
with | ̂|    
Proportion of Simulations 
with abs-value of |   |    
1 -0.0033 0.0733 0.0016 (≈8/5000) 0.0016 (≈8/5000) 
2  0.0011 0.0059 0.0000 (≈0/5000) 0.0000 (≈0/5000) 
3 3.6e-06 0.0069 0.0000 (≈0/5000) 0.0000 (≈0/5000) 
4 -0.0014 0.0069 0.0000 (≈0/5000) 0.0000 (≈0/5000) 
5  0.0020 0.0186   0.0022 (≈11/5000)    0.0020 (≈10/5000) 
14 
 





The theoretical results in Section 4 as well as the empirical results in Section 5 lead us to advocate for 
the reflection, geometric and uniform designs introduced and illustrated in Section 4 in designing for the 
assessment of parallelism for the two-logistic model in (2).  In terms of efficiencies, reflection designs 
are preferred.  Furthermore, in terms of straightforward ease-of-implementation, these same reflection 
designs are highly favorable since as noted above the researcher merely sketches the drug/compound 
logistic curves and reads off design support points at the intersections with cut lines at           and 
         .  (Geometric and uniform designs generally require optimal design software.)  The above 
simulation results confirm the favorable performance of these reflection designs even in small-to-
moderate sample size situations as described above in Table 5b..  The addition of design support points 
when using the reflection design over the theoretical two-point D-optimal designs in Figure 2 cannot be 
overstressed since researchers typically wish to both efficiently estimate model parameters and check 
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